Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk's Great Hope Semaglutide Shines In Ph II Obesity Study

Highly positive top-line weight loss results for Novo Nordisk's new GLP-1 agonist semaglutide are propelling it into Phase III trials next year for the notoriously tricky indication. The product is currently under review for type 2 diabetes.

Clinical Trials Companies Research & Development

This Means War: Identical Labels Recommended For Gilead, AbbVie's HCV Drugs In Europe

AbbVie and Gilead have won positive recommendations in Europe and matching eight-week dosing labels for their latest hepatitis C combination therapies, Maviret and Vosevi – now it's all about the price.

Approvals Infectious Diseases Pricing Strategies

Red Teaming: What Pharma Can Learn From The US Military

How the pharmaceutical industry can use a novel US military technique to hone critical decision making strategies and to underpin M&A target screening.

Leadership Business Strategies Market Intelligence

Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market

Portola prepares to launch new anticoagulant betrixaban in niche patient population of patients with acute medical illness at risk of VTE, following FDA approval, despite mixed Phase III data.

Approvals Launches Cardiovascular

 Recent Tweets from Scrip

Commercial Explore this Topic

Obituary: Lupin’s founder Desh Bandhu Gupta And His People Mantra

Lupin’s founder and chairman, Desh Bandhu Gupta, who died aged 79 on June 26, was known to give employees significant autonomy at the workplace, with some saying that people were the crux of his company-building mantra.

India Commercial Companies

If P&G Seeks OTC Sale, Pharma Buyers Might Line Up

P&G's activist investor Trian Fund Management is known for pressuring big companies to break up. The OTC business would likely have plenty of potential buyers.

Business Strategies Deals Consumer

Latest From Commercial

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

Leadership Financing

Podcast: Scaling Up Your Business

BIO International 2017 discussion: growing a biotech business. This content was produced by Scrip alongside a sponsored project with MSP, a provider of specialized science campuses in Manchester and Cheshire, UK.

Business Strategies StartUps and SMEs

Ranbaxy Case Churns As Singhs Face Fortis Sale Issues

Shares in India’s Fortis Hospital chain slide after Malaysia’s IHH Healthcare denies it is close to a purchase from cash-strapped tycoons Malvinder and Shivinder Singh, who continue to fight an arbitration order to pay hundreds of millions of dollars in compensation to Daiichi Sankyo over Ranbaxy.

India Business Strategies

Pfizer, Cipla Pledge Better Access To Affordable Cancer Therapies In Africa

Pfizer and Cipla have separately committed to expanding access to affordable oncology drugs in sub-Saharan Africa in collaboration with the American Cancer Society and the Clinton Health Access Initiative. The public-private alliances are expected to enable procurement of these medicines for the African nations at significant savings, which Cipla tells Scrip could be in the region of 20-30% initially.

Middle East and Africa Market Access

CHMP OK Puts Merck KGaA's Cladribine Pill On EU Home Stretch After Long Trek

Merck of Germany's oral multiple sclerosis medicine cladribine looks set to finally get EU approval. But the long, slow race it has had to endure - and time lost getting there - may curb sales.

Advisory Committees Approvals

Lifted Regulatory Overhang Raises Cadila’s Value

Cadila Healthcare, the listed flagship of billionaire Pankaj Patel’s Zydus Group, has become India’s second most valuable pharmaceutical firm after its shares were lifted by the resolution of US regulatory issues engulfing its biggest manufacturing plant, and a string of drug approvals.

India Commercial

Policy & Regulation Explore this Topic

Kamada's Plans For Emphysema Drug Delayed By Years After MAA Withdrawal

Kamada has withdrawn its European approval application for an inhaled version of its emphysema drug Glassia – a move that shocked investors because of the company's continued insistence data from a failed pivotal study would be enough to convince regulators.

Market Intelligence Respiratory Research and Development Strategies

EU CHMP OKs Imraldi, Samsung Bioepis’ Biosimilar Of AbbVie’s Humira

The EU’s CHMP has given the green light to Imraldi, Samsung Bioepis’ biosimilar version of AbbVie’s blockbuster adalimumab product Humira. If approved by the European Commission, this will be the South Korean company’s third biosimilar anti-TNF alpha product to gain a marketing authorization in the EU.

Approvals Europe

Novartis' Kisqali CHMP Nod In Fast-Moving Market

The likely upcoming EU approval of Kisqali, Novartis' answer to Pfizer's Ibrance, opens a new front in a breast cancer marketing battle that is likely to get more intense.

Approvals Companies

Melinta To Launch First Commercial Drug Baxdela Independently

Melinta is positioning its novel fluroquinolone antibiotic as an attractive option for seriously ill patients with underlying chronic conditions, but Baxdela will face challenges in a market dominated by generics.

Approvals Launches

Research & Development Explore this Topic

Pipeline Watch: Top-Line Phase III Canakinumab, Shingrix And Brolucizumab Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals Research & Development

Latest From Research & Development

Mixed Data For Bluebird's LentiGlobin, But Conditional Approval On The Cards

Over the last week bluebird bio has reported first interim Phase III data from the Northstar-2 trial of blood disease drug LentiGlobin and announced a public offering of $350m of common stock.

Blood & Coagulation Disorders Research and Development Strategies

Was PD-L1 Test To Blame For Failure Of Bristol's Opdivo In '026 Trial?

NEJM editorial suggests that differences in PD-L1 testing may explain why Bristol's Opdivo failed in first-line lung cancer trial whereas Merck's Keytruda succeeded, but some analysts aren't so sure.

ImmunoOncology Cancer

ASIT Biotech's Novel Grass Allergy Product Needs Second Phase III Study

Belgium’s ASIT biotech hopes to succeed in the difficult allergy market with a more focused Phase III study of its grass pollen allergy product, after its first Phase III study showed that the product significantly improved symptoms, but not to an extent to satisfy regulators.

Clinical Trials Immune Disorders